Skip to main content
Download PDF

Risk factors for radiation-induced lung injury in patients with advanced non-small cell lung cancer: implication for treatment strategies

World Journal of Surgical Oncology volume 19, Article number: 214 (2021) Cite this article

Abstract

Background

The radiation-induced lung injury (RILI) in patients with advanced non-small cell lung cancer (NSCLS) is very common in clinical settings; we aimed to evaluate the risk factors of RILI in NSCLS patients, to provide insights into the treatment of NSCLS.

Methods

NSCLC patients undergoing three-dimensional conformal radiotherapy (3D-CRT) in our hospital from June 1, 2018, to June 30, 2020, were included. The characteristics and treatments of RILI and non-RILI patients were analyzed. Logistic regression analyses were conducted to assess the risk factors of RILI in patients with NSCLC.

Results

A total of 126 NSCLC patients were included; the incidence of RILI in NSCLC patients was 35.71%. There were significant differences in diabetes, smoke, chronic obstructive pulmonary disease (COPD), concurrent chemotherapy, radiotherapy dose, and planning target volume (PTV) between the RILI group and the non-RILI group (all P < 0.05). Logistic regression analyses indicated that diabetes (OR 3.076, 95%CI 1.442~5.304), smoke (OR 2.745, 95%CI 1.288~4.613), COPD (OR 3.949, 95%CI 1.067~5.733), concurrent chemotherapy (OR 2.072, 95%CI 1.121~3.498), radiotherapy dose ≥ 60 Gy (OR 3.841, 95%CI 1.932~5.362), and PTV ≥ 396 (OR 1.247, 95%CI 1.107~1.746) were the independent risk factors of RILI in patients with NSCLC (all P < 0.05).

Conclusions

RILI is commonly seen in NSCLS patients; early targeted measures are warranted for patients with those risk factors; future studies with larger sample sizes and different areas are needed to further elucidate the influencing factors of RILI in the treatment of NSCLS.

Background

Non-small cell lung cancer (NSCLC) is a common type of clinical lung cancer, which accounts for about about 40% of the total number of lung cancers [1, 2]. Local radiotherapy treatment is an important treatment of NSCLC, and radiation-induced lung injury (RILI) is a common complication of thoracic radiation therapy. Once RILI occurs, it is often irreversible and significant [3]. Therefore, the early prevention and treatment of RILI are crucial to improve the prognosis of patients.

Three-dimensional conformal radiotherapy (3D-CRT) refers to multiple beam irradiation technology that uses a series of different weights, different field shapes, and sizes to irradiate the target area from different directions [4,5,6]. A conformal lead that is consistent with the shape of the lesion is used to make the high-dose area consistent with the shape of the target area in three-dimensional space and at the same time reduce the dose of normal tissues around the target area [7, 8]. RILI is one of the main side effects of thoracic cancer radiotherapy. The clinical incidence of RILI is reported in previous studies to be 5.12 to 36.07%, which can significantly affect the treatment and prognosis of patients [9,10,11]. Although 3D-CRT can reduce radiation damage to normal tissues through precise quantitative control of cancer radiation dose, the occurrence of RILI with clinical symptoms is still very common [12]. RILI patients have a series of non-specific respiratory symptoms due to severe lung injury, which will seriously affect the patient’s quality of life [13,14,15]. How to predict and prevent the occurrence of RILI has become an urgent problem to be solved in radiotherapy [16]. Therefore, we aimed to evaluate the risk factors of RILI in NSCLC patients, to provide insights into the clinical prevention and treatment of RILI.

Methods

Ethical considerations

In this study, all methods were performed in accordance with the relevant guidelines and regulations. This present study had been checked and approved by the ethical committee of our hospital (approval number: DE180042), all the participants had been well-informed, and written informed consents had been obtained from all the included patients.

Patients

This study selected NSCLC patients who underwent 3D-CRT in our hospital from June 1, 2018, to June 30, 2020, as study populations. The inclusion criteria of the patients were as follows: (1) patients were diagnosed with pathological examination as NSCLC [17, 18]; (2) age< 70 years old, (3) Karnofsky score ≥ 70 points, (4) patients received 3D-CRT, and (5) the follow-up period after radiotherapy was ≥ 6 months. The exclusion criteria for patients were as follows: (1) distant metastasis occurred during radiotherapy, (2) there were interruptions during radiotherapy > 1 week, (3) surgery treatment was performed during radiotherapy, and (4) patients were unwilling to participant in this present study.

3D-CRT

Gamma MEDx 100 (German) was used for the 3D-CRT. The patient was fixed with hydrolyzed plastic forming technology, and the arms are raised and crossed on the top of the forehead. The patient kept breathing calmly and performed a spiral CT scan, ranging from the midline of the neck to 3 cm below the diaphragm, including the whole lung tissue, with a thickness of 3 mm. The positioning image was obtained, the Z line value was approved, and the X, Y, and Z coordinates of the marked points on the patient’s body surface. For the parameters and repeated positioning readings, we used bony markers that are not easy to move as the marking points on the body surface and transmitting the positioning images obtained from the positioning scan to the Curer 8.0 treatment planning system via the network. Target area delineation: we delineated the gross tumor volume (GTV) layer by layer under the lung window of the CT image after the 3D reconstruction, and the clinical target volume (CTV) was obtained by placing 6 mm of squamous cell carcinoma GTV. For adenocarcinoma, GTV was placed 8 mm to obtain CTV, and CTV was expanded by 5 mm to obtain the planned target volume (PTV). If the patient’s lung function was poor or the CTV is large, the CTV should be manually modified according to the patient’s lung function status and breathing amplitude. We appropriately increased the scope of the patient’s upper and lower PTV extension up to 10~15 mm outside the CTV. The radiation therapy dose was 46~70 Gy (the median dose is 60 Gy), 5 times per week, 1.8~2.0 Gy per time. Normal tissue dose limits: spinal cord Dmax ≤ 45 Gy, esophagus Dmax ≤ 60 Gy, lung V5 ≤ 65%, lung V20 ≤ 25%, lung V30 ≤ 20%.

Chemotherapy

The chemotherapy regimen used in our study was as follows: paclitaxel (Xinwei, Shanghai, S0190335) or docetaxel (Gynesier, German, C901241511) + cisplatin (Minhua, Shenzhen, W291101) or carboplatin (Huangchen, Zhengzhou, 1910418). The first-line regimen of intravenous infusion of paclitaxel (135~175 mg m−2) (day 1), docetaxel (65~75 mg m−2) (day 1), cisplatin (80–100 mg m−2) (days 2 and 3), and carboplatin (300–350 mg m−2) (day 2). At 21–28 days for 1 cycle, a total of 2 to 6 cycles were completed.

Diagnostic criteria of RILI

RILI toxicity was assessed with the Common Terminology Criteria for Adverse Events version 4.0, which was divided into 0 to 5 levels: grade 0—no obvious symptoms or signs change before and after treatment; grade 1—mild cough or shortness of breath after radiotherapy; grade 2—cough was persistent and requires medicine to relieve it and asthma after exercise; grade 3: severe cough, asthma, and shortness of breath were presented in the resting state, which could not be relieved by drugs, and the imaging examination revealed radiation pneumonia. Glucocorticoid therapy was effective; grade 4—dyspnea, oxygen, or assisted ventilation; and grade 5—patient death due to ventilatory failure and lung failure.

Data collection

Two authors collected the following personal characteristics and treatment data of patients: gender, age, body mass index (BMI), diabetes, hypertension, hyperlipidemia, smoke, chronic obstructive pulmonary disease (COPD), pathological type, concurrent chemotherapy, Karnofsky percent score (KPS), tumor staging, cancer size, radiotherapy dose (Gy), V5, V10, V20, V30, MLD, GTV, and PTV.

Statistical analysis

We used the SPSS 24.0 statistical software for statistical analysis. Enumeration data was expressed as cases and percentages, and the chi-square test was used for comparison between the groups; measurement data was expressed as mean ± standard deviation, and the t test was used for comparison between the groups. Logistic regression analyses were conducted to assess the risk factors of RILI in patients with NSCLC. P < 0.05 indicates that the difference was statistically significant.

Results

The characteristics of included patients

A total of 126 NSCLC patients were included, of whom 45 patients had RILI; the incidence of RILI in NSCLC patients was 35.71%. As presented in Table 1, there were significant differences in diabetes, smoke, COPD, concurrent chemotherapy, radiotherapy dose, and PTV between the RILI group and non-RILI group (all P < 0.05). But no significant differences in gender, age, BMI, hypertension, hyperlipidemia, pathological type, KPS, tumor staging, cancer size, V5, V10, V20, V30, MLD, and GTV between the RILI group and the non-RILI group were found (all P > 0.05).

Table 1 The characteristics of included patients
Full size table

Logistic regression analysis on the risk factors of RILI in patients with NSCLC

The variable assignments of multivariate logistic regression were presented in Table 2. As indicated in Table 3, diabetes (OR 3.076, 95%CI 1.442~5.304), smoke (OR 2.745, 95%CI 1.288~4.613), COPD (OR 3.949, 95%CI 1.067~5.733), concurrent chemotherapy (OR 2.072, 95%CI 1.121~3.498), radiotherapy dose ≥ 60 Gy (OR 3.841, 95%CI 1.932~5.362), and PTV ≥ 396 (OR 1.247, 95%CI 1.107~1.746) were the independent risk factors of RILI in patients with NSCLC (all P < 0.05).

Table 2 The variable assignment of multivariate logistic regression
Full size table
Table 3 The logistic regression analysis on the risk factors of RILI in patients with NSCLC
Full size table

Discussions

RILI is one of the important toxic reactions of radiotherapy in the treatment of thoracic tumors. RILI often appears during radiotherapy to 3 months after radiotherapy [19, 20]. It usually manifests as dry cough, fever, shortness of breath, etc. In severe cases, severe breathing difficulties, respiratory failure, and even death can occur. Numerous studies [21,22,23,24] have shown that clinical factors, therapeutic factors, metrological factors, and biological factors are closely related to the occurrence of RILI. The results of this study have shown that diabetes, smoke, COPD, concurrent chemotherapy, radiotherapy dose ≥ 60 Gy, and PTV ≥ 396 were the independent risk factors of RILI in patients with NSCLC; special attentions and early interventions are needed for NSCLC patients with those risk factors.

In this study, the incidence of RILI in NSCLC patients that received 3D-CRT was 35.71%, which is consistent with several previous studies [25, 26]. It has been found that the incidence of RILI in patients receiving concurrent chemotherapy is 63.17%, while the incidence of RILI in patients who did not undergo chemotherapy is only 16%, and the incidence of RILI is higher in patients who received paclitaxel + carboplatin [27,28,29,30]. We have found that whether to receive concurrent chemotherapy is significantly related to the incidence of RILI, which may be associated with the fact that patients undergoing chemotherapy treatment are prone to lower immune levels and higher organ sensitivity. It has been found that MLD and the percentage of the total lung volume (lung V5, V10, V20, V30, V40, V50, and V60) of the lung volume that received more than a certain dose of irradiation are independent risk factors for RP after 3D-CRT treatment of NSCLC [31,32,33]. Besides, it has been reported that MLD, V20, V30, V40, and V50 have predictive significance for RILI in NSCLC patients treated with radiotherapy and chemotherapy [34].

Diabetes, smoking, and COPD are risk factors related to RILI. This study shows that smoking is a risk factor for RILI. Some studies [14, 35, 36] have shown that smoking is an independent protective factor for RP. It is considered that the hypoxia and immunosuppression caused by smoking may be related to the increased lung tolerance of smoking patients [37]. Studies [30, 38] have pointed out that factors such as smoking, COPD, and ventilatory dysfunction can increase the risk of RILI. It is recommended that lung diffusion function be tested before radiotherapy to evaluate lung function status [39]. Therefore, in radiotherapy, attention should be paid to the exposure volume and exposure dose [40]. At the same time, if the patient has diabetes, smoking, COPD, concurrent chemotherapy, and radiotherapy, the total dose should be optimized and preventive measures should be taken to reduce the occurrence of RILI [41]. Previous studies [42, 43] have shown that complications such as chronic obstructive pulmonary disease and ventilatory dysfunction caused by smoking can increase the risk of lung injury. It is recommended that the lung diffusion function be tested before radiotherapy to evaluate the status of lung function.

This study also has certain shortcomings that must be considered. Firstly, the sample size of this study, especially the number of cases in the RILI group, was small, so the statistical efficiency might be underpowered to detect the potential difference. Secondly, given the limited data, we could not do further subgroup analysis on the severity of RILI. Thirdly, radiation-induced lung injuries can also appear after 3 months, limited by collected data; we only analyzed the radiation-induced lung injuries within 3 months; future studies with longer follow-up are needed. Besides, there may be certain differences in radiotherapy doses and schedules in various hospitals, and future large-sample multi-center studies are needed to further analyze and explore related influencing factors of RILI in NSCLC patients.

Conclusions

In conclusion, we have found that the incidence of RILI in NSCLC patients is 35.71%, and for patients with diabetes, smoke, COPD, concurrent chemotherapy, radiotherapy dose≥60Gy, and PTV ≥ 396, they may have higher risk factors of RILI; early alert and preventative measures are needed for those patients. At present, the prevention and treatment of RILI are still a difficult problem to solve, and its occurrence is related to many factors. It must be noted that our cohort may be exceedingly small heterogenous that cannot be applied to a larger cohort limited by the small sample size. The clinical value of the observation indicators in this study needs to be further verified in future studies. Moreover, the mechanism of RILI and related influencing factors also needs to be explored in the future.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Abbreviations

RILI:

Radiation-induced lung injury

NSCLS:

Non-small cell lung cancer

COPD:

Chronic obstructive pulmonary disease

PTV:

Planning target volume

3D-CRT:

Three-dimensional conformal radiotherapy

GTV:

Gross tumor volume

CTV:

Clinical target volume

BMI:

Body mass index

KPS:

Karnofsky percent score

References

  1. Ye Z, Huang Y, Ke J, Zhu X, Leng S, Luo H. Breakthrough in targeted therapy for non-small cell lung cancer. Biomed Pharmacother. 2021;133:111079. https://doi.org/10.1016/j.biopha.2020.111079.

    Article  CAS  PubMed  Google Scholar 

  2. Feng L, Wang Z, Jing L, Zhou Z, Shi S, Deng R, et al. Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis. World J Surg Oncol. 2021;19(1):64. https://doi.org/10.1186/s12957-021-02161-1.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Bernchou U, Christiansen RL, Asmussen JT, Schytte T, Hansen O, Brink C. Extent and computed tomography appearance of early radiation induced lung injury for non-small cell lung cancer. Radiother Oncol. 2017;123(1):93–8. https://doi.org/10.1016/j.radonc.2017.02.001.

    Article  PubMed  Google Scholar 

  4. Wei X, Jiang Y, Zhang X, Feng S, Zhou B, Ye X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study. J Clin Oncol. 2019;37(24):2141–51. https://doi.org/10.1200/JCO.18.02184.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Hirose TA, Arimura H, Ninomiya K, Yoshitake T, Fukunaga JI, Shioyama Y. Radiomic prediction of radiation pneumonitis on pretreatment planning computed tomography images prior to lung cancer stereotactic body radiation therapy. Sci Rep. 2020;10(1):20424. https://doi.org/10.1038/s41598-020-77552-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Farr KP, Khalil AA, Grau C. Patient-reported lung symptoms and quality of life before and after radiation therapy for non-small cell lung cancer: correlation with radiation pneumonitis and functional imaging. Acta Oncol. 2019;58(10):1523–7. https://doi.org/10.1080/0284186X.2019.1634835.

    Article  PubMed  Google Scholar 

  7. Jirkovska M, Novak T, Malinova B, Lohynska R. Three-dimensional conformal radiotherapy versus intensity modulated radiotherapy with simultaneous integrated boost in the treatment of locally advanced head and neck carcinoma. Neoplasma. 2019;66(5):830–8. https://doi.org/10.4149/neo_2018_181209N941.

    Article  CAS  PubMed  Google Scholar 

  8. Sukari A, Nagasaka M, Alhasan R, Patel D, Wozniak A, Ramchandren R, et al. Cancer site and adverse events induced by immune checkpoint inhibitors: a retrospective analysis of real-life experience at a single institution. Anticancer Res. 2019;39(2):781–90. https://doi.org/10.21873/anticanres.13175.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Peng F, Stanton P, Bi N, Kong F. Dose-related changes for lung ventilation and perfusion and prediction for radiation-induced lung injury during the course of radiotherapy in patients with non-small cell lung cancer. Pract Radiat Oncol. 2013;3(2 Suppl 1):S26. https://doi.org/10.1016/j.prro.2013.01.091.

    Article  CAS  PubMed  Google Scholar 

  10. Wang D, Sun J, Zhu J, Li X, Zhen Y, Sui S. Functional dosimetric metrics for predicting radiation-induced lung injury in non-small cell lung cancer patients treated with chemoradiotherapy. Radiat Oncol. 2012;7(1):69. https://doi.org/10.1186/1748-717X-7-69.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Zhong L, Suo J, Wang Y, Han J, Zhou H, Wei H, et al. Prognosis of limited-stage small cell lung cancer with comprehensive treatment including radical resection. World J Surg Oncol. 2020;18(1):27. https://doi.org/10.1186/s12957-020-1807-1.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Itamura H, Ohguri T, Yahara K, Nakahara S, Kakinouchi S, Morisaki T, et al. Pembrolizumab-induced radiation recall pneumonitis after the resolution of typical asymptomatic radiation pneumonitis. J UOEH. 2020;42(3):261–6. https://doi.org/10.7888/juoeh.42.261.

    Article  PubMed  Google Scholar 

  13. Shi L, He Y, Yuan Z, Benedict S, Valicenti R, Qiu J, et al. Radiomics for response and outcome assessment for non-small cell lung cancer. Technol Cancer Res Treat. 2018;17:1533033818782788.

    Article  Google Scholar 

  14. Palma G, Monti S, Thor M, Rimner A, Deasy JO, Cella L. Spatial signature of dose patterns associated with acute radiation-induced lung damage in lung cancer patients treated with stereotactic body radiation therapy. Phys Med Biol. 2019;64(15):155006. https://doi.org/10.1088/1361-6560/ab2e16.

    Article  CAS  PubMed  Google Scholar 

  15. Li YQ, Zheng Z, Liu QX, Lu X, Zhou D, Zhang J, et al. Moesin as a prognostic indicator of lung adenocarcinoma improves prognosis by enhancing immune lymphocyte infiltration. World J Surg Oncol. 2021;19(1):109. https://doi.org/10.1186/s12957-021-02229-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Chang SC, Lai YC, Hung JC, Chang CY. Oral glutamine supplements reduce concurrent chemoradiotherapy-induced esophagitis in patients with advanced non-small cell lung cancer. Medicine (Baltimore). 2019;98(8):e14463. https://doi.org/10.1097/MD.0000000000014463.

    Article  CAS  Google Scholar 

  17. Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–40. https://doi.org/10.1016/j.mayocp.2019.01.013.

    Article  CAS  PubMed  Google Scholar 

  18. Reck M, Rabe KF. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med. 2017;377(9):849–61. https://doi.org/10.1056/NEJMra1703413.

    Article  CAS  PubMed  Google Scholar 

  19. Jahangiri P, Pournazari K, Torigian DA, Werner TJ, Swisher-McClure S, Simone CB 2nd, et al. A prospective study of the feasibility of FDG-PET/CT imaging to quantify radiation-induced lung inflammation in locally advanced non-small cell lung cancer patients receiving proton or photon radiotherapy. Eur J Nucl Med Mol Imaging. 2019;46(1):206–16. https://doi.org/10.1007/s00259-018-4154-5.

    Article  PubMed  Google Scholar 

  20. Hanaoka J, Yoden M, Hayashi K, Shiratori T, Okamoto K, Kaku R, et al. Dynamic perfusion digital radiography for predicting pulmonary function after lung cancer resection. World J Surg Oncol. 2021;19(1):43. https://doi.org/10.1186/s12957-021-02158-w.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Li Q, Liu Y, Su B, Zhao H, Lin Q, Zhu Y, et al. The CT appearance pattern of radiation-induced lung injury and tumor recurrence after stereotactic body radiation therapy in early stage non-small cell lung cancer. Transl Lung Cancer Res. 2020;9(3):713–21. https://doi.org/10.21037/tlcr-20-609.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Mehta V. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer. Semin Oncol. 2004;31(6 Suppl 18):42–6. https://doi.org/10.1053/j.seminoncol.2004.12.011.

    Article  CAS  PubMed  Google Scholar 

  23. Chen J, Lu JJ, Ma N, Zhao J, Chen C, Fan M, et al. Early stage non-small cell lung cancer treated with pencil beam scanning particle therapy: retrospective analysis of early results on safety and efficacy. Radiat Oncol. 2019;14(1):16. https://doi.org/10.1186/s13014-019-1216-1.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Wu LL, Lai JJ, Liu X, Huang YY, Lin P, Long H, et al. Association between number of dissected lymph nodes and survival in stage IA non-small cell lung cancer: a propensity score matching analysis. World J Surg Oncol. 2020;18(1):322. https://doi.org/10.1186/s12957-020-02090-5.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Zhang H, Jiang T, Yu H, Lu H, Zhao Y, Zhang Y, et al. Polyene phosphatidylcholine protects against radiation induced tissue injury without affecting radiotherapeutic efficacy in lung cancer. Am J Cancer Res. 2019;9(6):1091–103.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Moran A, Daly ME, Yip SSF, Yamamoto T. Radiomics-based assessment of radiation-induced lung injury after stereotactic body radiotherapy. Clin Lung Cancer. 2017;18(6):e425–31. https://doi.org/10.1016/j.cllc.2017.05.014.

    Article  CAS  PubMed  Google Scholar 

  27. Torre-Bouscoulet L, Munoz-Montano WR, Martinez-Briseno D, Lozano-Ruiz FJ, Fernandez-Plata R, Beck-Magana JA, et al. Abnormal pulmonary function tests predict the development of radiation-induced pneumonitis in advanced non-small cell lung cancer. Respir Res. 2018;19(1):72. https://doi.org/10.1186/s12931-018-0775-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Itonaga T, Sugahara S, Mikami R, Saito T, Yamada T, Kurooka M, et al. Evaluation of the relationship between the range of radiation-induced lung injury on CT images after IMRT for stage I lung cancer and dosimetric parameters. Ann Med. 2021;53(1):267–73. https://doi.org/10.1080/07853890.2020.1869297.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Sheng Y, Chen K, Jiang W, Wu Z, Zhang W, Jing H, et al. PD-1 restrains IL-17A production from gammadelta T cells to modulate acute radiation-induced lung injury. Transl Lung Cancer Res. 2021;10(2):685–98. https://doi.org/10.21037/tlcr-20-838.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Menoux I, Antoni D, Mazzara C, Labani A, Charloux A, Quoix E, et al. Radiation-induced lung toxicity predictors: retrospective analysis of 90 patients treated with stereotactic body radiation therapy for stage I non-small-cell lung carcinoma. Cancer Radiother. 2020;24(2):120–7. https://doi.org/10.1016/j.canrad.2019.11.003.

    Article  CAS  PubMed  Google Scholar 

  31. Yue J, Shi Q, Xu T, Jeter M, Chen TY, Komaki R, et al. Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study. Qual Life Res. 2018;27(6):1563–70. https://doi.org/10.1007/s11136-018-1834-3.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Wang W, Men Y, Wang J, Zhou Z, Chen D, Xiao Z, et al. Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung cancer after pneumonectomy. BMC Cancer. 2019;19(1):478. https://doi.org/10.1186/s12885-019-5692-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Zhou Y, Yan T, Zhou X, Cao P, Luo C, Zhou L, et al. Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: impact of pre-treatment pulmonary function parameters. Strahlenther Onkol. 2020;196(6):505–14. https://doi.org/10.1007/s00066-019-01552-4.

    Article  PubMed  Google Scholar 

  34. Xiao L, Yang G, Chen J, Yang Y, Meng X, Wang X, et al. Comparison of predictive powers of functional and anatomic dosimetric parameters for radiation-induced lung toxicity in locally advanced non-small cell lung cancer. Radiother Oncol. 2018;129(2):242–8. https://doi.org/10.1016/j.radonc.2018.09.005.

    Article  PubMed  Google Scholar 

  35. Nakajima M, Yamamoto N, Hayashi K, Karube M, Ebner DK, Takahashi W, et al. Carbon-ion radiotherapy for non-small cell lung cancer with interstitial lung disease: a retrospective analysis. Radiat Oncol. 2017;12(1):144. https://doi.org/10.1186/s13014-017-0881-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Menoux I, Le Fevre C, Noel G, Antoni D. Radiation-induced lung toxicity predictors after stereotactic radiation therapy for non-small cell lung carcinoma stage I. Cancer Radiother. 2018;22(8):826–38. https://doi.org/10.1016/j.canrad.2017.12.007.

    Article  CAS  PubMed  Google Scholar 

  37. Ireland RH, Din OS, Swinscoe JA, Woodhouse N, van Beek EJ, Wild JM, et al. Detection of radiation-induced lung injury in non-small cell lung cancer patients using hyperpolarized helium-3 magnetic resonance imaging. Radiother Oncol. 2010;97(2):244–8. https://doi.org/10.1016/j.radonc.2010.07.013.

    Article  PubMed  Google Scholar 

  38. Kalman NS, Hugo GD, Mahon RN, Deng X, Mukhopadhyay ND, Weiss E. Diabetes mellitus and radiation induced lung injury after thoracic stereotactic body radiotherapy. Radiother Oncol. 2018;129(2):270–6. https://doi.org/10.1016/j.radonc.2018.08.024.

    Article  PubMed  Google Scholar 

  39. Liu Y, Zhu Y, Wu R, Hu M, Zhang L, Lin Q, et al. Stereotactic body radiotherapy for early stage non-small cell lung cancer in patients with subclinical interstitial lung disease. Transl Lung Cancer Res. 2020;9(6):2328–36. https://doi.org/10.21037/tlcr-20-1050.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Nobashi TW, Nishimoto Y, Kawata Y, Yutani H, Nakamura M, Tsuji Y, et al. Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers. Br J Radiol. 2020;93(1115):20200409. https://doi.org/10.1259/bjr.20200409.

    Article  PubMed  Google Scholar 

  41. Bousabarah K, Temming S, Hoevels M, Borggrefe J, Baus WW, Ruess D, et al. Radiomic analysis of planning computed tomograms for predicting radiation-induced lung injury and outcome in lung cancer patients treated with robotic stereotactic body radiation therapy. Strahlenther Onkol. 2019;195(9):830–42. https://doi.org/10.1007/s00066-019-01452-7.

    Article  PubMed  Google Scholar 

  42. Evison M, Barrett E, Cheng A, Mulla A, Walls G, Johnston D, et al. Predicting the risk of disease recurrence and death following curative-intent radiotherapy for non-small cell lung cancer: the development and validation of two scoring systems from a large multicentre UK cohort. Clin Oncol (R Coll Radiol). 2021;33(3):145–54. https://doi.org/10.1016/j.clon.2020.09.001.

    Article  CAS  Google Scholar 

  43. Shintani T, Kishi N, Matsuo Y, Ogura M, Mitsuyoshi T, Araki N, et al. Incidence and risk factors of symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy and consolidation durvalumab. Clin Lung Cancer. 2021. https://doi.org/10.1016/j.cllc.2021.01.017.

Download references

Acknowledgements

None.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Radiotherapy, Jiaozhou Central Hospital, No. 29 Xuzhou Road, Jiaozhou City, Qingdao, 266300, China

    Sha Sha, Jigang Dong, Maoyu Wang, Ziyu Chen & Peng Gao

Authors
  1. Sha Sha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jigang Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maoyu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ziyu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peng Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SS designed the research. JD, MW, ZC, and PG conducted the research. SS, JD, and MW analyzed the data. SS wrote the first draft of the manuscript. SS had primary responsibility for the final content. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Sha Sha.

Ethics declarations

Ethics approval and consent to participate

In this study, all methods were performed in accordance with the relevant guidelines and regulations. This present study had been checked and approved by the ethical committee of our hospital (approval number: DE180042), all the participants had been well-informed, and written informed consents had been obtained from all the included patients.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sha, S., Dong, J., Wang, M. et al. Risk factors for radiation-induced lung injury in patients with advanced non-small cell lung cancer: implication for treatment strategies. World J Surg Onc 19, 214 (2021). https://doi.org/10.1186/s12957-021-02321-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12957-021-02321-3

Keywords

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us